11:10 AM EST - BriaCell Therapeutics Corp. : Has completed manufacturing clinical supplies of Bria-PROS+, its next generation, personalized, off-the-shelf, cell-based immunotherapy candidate for prostate cancer. BriaCell Therapeutics Corp.
shares T.BCT are trading unchanged at $5.72.
